Multiple tumor-associated and minor histocompatibility antigens presented on peptide-HLA complexes

The target "Multiple tumor-associated and minor histocompatibility antigens presented on peptide-HLA complexes" refers to a diverse set of antigenic peptides derived from intracellular proteins that are displayed on the cell surface by Human Leukocyte Antigen (HLA) molecules. These antigens include tumor-associated antigens (TAAs), which are self-proteins overexpressed or aberrantly expressed in cancer cells, and minor histocompatibility antigens (miHAs), which are polymorphic peptides that differ between individuals and are particularly relevant in allogeneic hematopoietic stem cell transplantation. These peptide-HLA (pHLA) complexes are the primary targets for T-cell receptors (TCRs) on cytotoxic T lymphocytes, triggering an immune response upon binding. Therapeutic strategies targeting these complexes include multi-antigen vaccines, TCR-engineered T-cell therapies (TCR-T), and multi-antigen-specific T-cell products. By targeting multiple antigens simultaneously, these therapies aim to overcome tumor heterogeneity and prevent immune escape, while miHA-specific approaches leverage the graft-versus-leukemia effect to eradicate residual disease in transplant settings.

Other names

Peptide-HLA complexpHLApMHCTumor-associated antigens (TAAs)Minor histocompatibility antigens (miHAs)MHC-associated antigensMHC-peptide complex

T-cell receptor (TCR) binding and activation leading to targeted cytotoxicity against cells presenting the specific peptide-HLA complexes.